Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit Against Delcath Systems, Inc.



  Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit Against Delcath
  Systems, Inc.

Business Wire

LOS ANGELES -- May 20, 2013

Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been
filed in the United States District Court for the Southern District of New
York on behalf of a class (the “Class”) comprising all purchasers of the
securities of Delcath Systems, Inc. (“Delcath” or the “Company”) (NASDAQ:DCTH)
between April 21, 2010 and May 2, 2013, inclusive (the “Class Period”).

A COPY OF THE COMPLAINT IS AVAILABLE FROM THE COURT OR FROM GLANCY BINKOW &
GOLDBERG LLP. PLEASE CONTACT US TOLL-FREE AT (888) 773-9224, AT (212) 682-5340
OR AT SHAREHOLDERS@GLANCYLAW.COM. IF YOU INQUIRE BY EMAIL PLEASE INCLUDE YOUR
MAILING ADDRESS, TELEPHONE NUMBER AND NUMBER OF SHARES PURCHASED.

Delcath operates as a specialty pharmaceutical and medical device company
focusing on the field of oncology, primarily the development of
CHEMOSAT/Melblez Kit system, which administers concentrated regional
chemotherapy to the liver. The Complaint alleges that throughout the Class
Period defendants misrepresented or failed to disclose material adverse facts
about, among other things, the Company's New Drug Application seeking Food and
Drug Administration (FDA) approval for commercial sale of Melblez Kit --
Melblez (melphalan) for Injection for use with the Delcath Hepatic Delivery
System -- for the treatment of patients with unresectable ocular melanoma
metastatic to the liver, including substantial and severe toxicity, and deaths
associated with the drug’s adverse reactions.

On May 2, 2013 the Company disclosed that the FDA’s Oncologic Drugs Advisory
Committee voted 16-0, with no abstentions, that Melblez Kit’s treatment
benefits do not outweigh the risks associated with the procedure. The next
day, as a result of this news, the price of Delcath shares dropped more than
40% on extremely heavy trading volume.

If you are a member of the Class described above and meet certain legal
requirements, you may move the Court no later than July 8, 2013 to serve as
lead plaintiff. To learn more, or if you purchased Delcath stock prior to the
Class Period, please contact Michael Goldberg, Esquire, of Glancy Binkow &
Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California
90067, Toll Free at (888) 773-9224, or contact Gregory Linkh, Esquire, of
Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New
York 10168, at (212) 682-5340, by e-mail to shareholders@glancylaw.com, or
visit our website at http://www.glancylaw.com. If you inquire by email please
include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

Contact:

Glancy Binkow & Goldberg LLP, Los Angeles, CA
Michael Goldberg
(888) 773-9224
or
Glancy Binkow & Goldberg LLP, New York, NY
Gregory Linkh
(212) 682-5340
shareholders@glancylaw.com
www.glancylaw.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement